Zerion Pharma A/S is a pharmaceutical company aspiring to transform the pharmaceutical landscape for formulation of poorly soluble drugs that are currently not reaching their therapeutic potential. The company was established in 2019 as a spinout from the University of Copenhagen based on a decade of research. Through the use of our proprietary Dispersome® formulation platform, we aim to develop new treatment options for patients across all small molecule therapy areas. We are focused on improving existing drug products by building an internal pipeline, while partnering with originators to enable their early-stage drug molecules, striving to improve the lives of patients around the world.
Our Dispersome® platform is based around a class of novel excipient, namely beta-lactoglobulin (BLG), to formulate poorly soluble small molecule drugs into stable amorphous drug delivery systems with a high drug load. By increasing solubility and dissolution rate the Dispersome platform aims at improving bioavailability and therapeutic outcomes and reducing adverse effects in patients. Dispersome is well accepted with no safety risks and compatible with standard solid oral dosage form manufacturing.